“Antigen-naive” (naive and transitional) and CD27+ “antigen-experienced” B cells in patients after HSCT
| B-cell subset . | Active, n = 22 . | Inactive, n = 23 . | No, n = 12 . | Healthy, n = 33 . |
|---|---|---|---|---|
| Total naive B cells ×1000/L | 79.8 | 99.1 | 260.5 | 89.5 |
| P vs none | .001 | .001 | .001 | |
| Total transitional B cells ×1000/L | 8.1 | 8.5 | 28.7 | 14.4 |
| P vs none | .04 | .04 | .02 | |
| Total CD27+CD19+ B cells ×1000/L | 17.5 | 25.3 | 24.9 | 68.1 |
| P vs none | .14 | .37 | .01 | |
| CD27+ B cells, % | 19.0 | 8.4 | 6.05 | 27.3 |
| P vs none | .06 | .21 | < .001 |
| B-cell subset . | Active, n = 22 . | Inactive, n = 23 . | No, n = 12 . | Healthy, n = 33 . |
|---|---|---|---|---|
| Total naive B cells ×1000/L | 79.8 | 99.1 | 260.5 | 89.5 |
| P vs none | .001 | .001 | .001 | |
| Total transitional B cells ×1000/L | 8.1 | 8.5 | 28.7 | 14.4 |
| P vs none | .04 | .04 | .02 | |
| Total CD27+CD19+ B cells ×1000/L | 17.5 | 25.3 | 24.9 | 68.1 |
| P vs none | .14 | .37 | .01 | |
| CD27+ B cells, % | 19.0 | 8.4 | 6.05 | 27.3 |
| P vs none | .06 | .21 | < .001 |